Apellis shares tumble on reports of eye inflammation in patients taking Syfovre

Apel­lis Phar­ma­ceu­ti­cals took a 21% hit to its stock price $APLS on Mon­day morn­ing, wip­ing $2 bil­lion from its mar­ket cap af­ter a group of reti­nal physi­cians warned its mem­bers about po­ten­tial safe­ty is­sues with the com­pa­ny’s ge­o­graph­ic at­ro­phy treat­ment Syfovre.

The Amer­i­can So­ci­ety of Reti­na Spe­cial­ists (ASRS) is­sued the warn­ing on Sat­ur­day, say­ing it’s re­ceiv­ing re­ports from physi­cians about in­traoc­u­lar in­flam­ma­tion in pa­tients who re­ceived the in­jec­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN